Pacira BioSciences

PCRX

Market cap $901M

PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript

Pacira (PCRX) came out with quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.91 per share a year ago.

— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years —

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction (“NOPAIN”) Act.

BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company.

Pacira BioSciences trades at distressed levels due to fears of EXPAREL patent erosion, despite strong cash flow and 78% gross margins. EXPAREL's manufacturing complexity and hospital adoption create a significant moat, making immediate generic substitution unlikely even after patent setbacks. The NOPAIN Act introduces a major reimbursement tailwind, shifting EXPAREL from a hospital cost burden to a neutral or positive economic choice.

Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.